Keyphrases
Tumor Growth
100%
Estrogen Receptor
100%
Receptor-independent
100%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
100%
Tumor Cells
29%
4-hydroxytamoxifen
29%
Neurofibromatosis Type I
11%
Neurofibromatosis Type 1 (NF-1)
11%
17-estradiol
11%
Tumor Cell Proliferation
11%
Tumor Cell Survival
11%
Mitogenesis
11%
Clinical Observation
5%
Clinical Trials
5%
Antitumor Activity
5%
Estrogen
5%
Receptor-interacting Protein Kinase 1 (RIPK1)
5%
Tumor Cell Lines
5%
Ablation
5%
Tumorigenesis
5%
Therapeutic Potential
5%
Tumor Proliferation
5%
Tumor Cell Death
5%
Biosynthetic Enzymes
5%
Tumor Xenograft
5%
Calmodulin
5%
Plexiform Neurofibroma
5%
Selective Estrogen Receptor Modulators
5%
Steroidal
5%
Malignancy-associated
5%
G Protein-coupled
5%
Trifluoperazine
5%
Tamoxifen Sensitivity
5%
ICI 182,780
5%
Antiestrogen
5%
Nerve Sheath Tumor
5%
GPER1
5%
Medicine and Dentistry
Estrogen Receptor
100%
Tumor Progression
100%
Tamoxifen
100%
Malignant Peripheral Nerve Sheath Tumor
100%
Tumor Cell
50%
Afimoxifene
31%
Cell Survival
12%
Cell Proliferation
12%
Neurofibromatosis Type I
12%
Diethylstilbestrol
12%
Mitogenesis
12%
Clinical Observation
6%
In Vitro
6%
Clinical Trial
6%
Cancer
6%
Cell Death
6%
Carcinogenesis
6%
Antineoplastic Activity
6%
Guanine Nucleotide Binding Protein
6%
Plexiform Neurofibroma
6%
Tumor Xenograft
6%
Malignant Peripheral Nerve Sheath Tumor Cell Line
6%
Nerve Sheath Tumor
6%
Antiestrogen
6%
Selective Estrogen Receptor Modulator
6%
G Protein Coupled Receptor 30
6%
Trifluoperazine
6%
Calmodulin
6%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Growth
100%
Estrogen Receptor
100%
Tamoxifen
100%
Malignant Peripheral Nerve Sheath Tumor
100%
Afimoxifene
29%
Neurofibromatosis Type 1
11%
Diethylstilbestrol
11%
Clinical Trial
5%
Carcinogenesis
5%
Antitumor Activity
5%
Guanine Nucleotide Binding Protein
5%
Antiestrogen
5%
Neurofibroma
5%
Trifluoperazine
5%
G Protein Coupled Receptor 30
5%
Selective Estrogen Receptor Modulator
5%
Nerve Sheath Tumor
5%
Calmodulin
5%